10m
Did UBS’s Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative?
In early January 2026, UBS upgraded Bristol-Myers Squibb after highlighting its broad drug pipeline, new clinical trial initiations, and progress on products aimed at easing upcoming patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback